Neuronetics Inc (NASDAQ:STIM) Reports Mixed Q2 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss

Neuronetics Inc (NASDAQ:STIM) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. While revenue exceeded estimates, the company's earnings per share (EPS) fell short, contributing to a sharp pre-market decline of approximately 9%.

Key Financial Highlights

• Revenue: The company posted $38.1 million in total revenue for Q2 2025, surpassing analyst estimates of $37.5 million. This represents an 18% adjusted pro forma growth compared to the prior year.
• EPS: Neuronetics reported a loss of $0.15 per share, significantly wider than the estimated loss of $0.0782.
• Greenbrook Clinic Performance: The company achieved record revenue of $23.0 million from its Greenbrook treatment centers, underscoring continued demand for its NeuroStar Advanced Therapy System.

Market Reaction

The stock’s pre-market drop suggests investor disappointment with the wider-than-expected loss, despite the revenue beat. Over the past month, shares had risen nearly 38%, likely reflecting optimism around growth prospects. However, the post-earnings decline indicates that profitability concerns are weighing on sentiment.

Analyst Estimates vs. Outlook

Looking ahead, analysts project:

• Q3 2025 Revenue: $39.1 million
• Q3 2025 EPS: -$0.068
• Full-Year 2025 Revenue: $153.7 million
• Full-Year 2025 EPS: -$0.364

The press release did not provide an explicit financial outlook, making it difficult to assess whether management’s expectations align with consensus estimates.

Press Release Summary

The earnings report emphasized strong revenue growth, particularly in Greenbrook clinics, but did not address the widening losses in detail. The company continues to focus on expanding its NeuroStar therapy for major depressive disorder (MDD) and other neurohealth conditions, having delivered over 7.1 million treatments to date.

For a deeper dive into Neuronetics’ earnings and future estimates, visit the earnings and estimates page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.